Pravdic, Zlatko (57221636770)Zlatko (57221636770)PravdicMitrovic, Mirjana (54972086700)Mirjana (54972086700)MitrovicBogdanovic, Andrija (6603686934)Andrija (6603686934)BogdanovicVirijevic, Marijana (36969618100)Marijana (36969618100)VirijevicSabljic, Nikica (57221634280)Nikica (57221634280)SabljicPantic, Nikola (57221630977)Nikola (57221630977)PanticVukovic, Nada Suvajdzic (36446767400)Nada Suvajdzic (36446767400)Vukovic2025-06-122025-06-122021https://doi.org/10.1055/a-1554-6432https://www.scopus.com/inward/record.uri?eid=2-s2.0-85115931532&doi=10.1055%2fa-1554-6432&partnerID=40&md5=f61a3aac8819541b35a003d74957e9dahttps://remedy.med.bg.ac.rs/handle/123456789/4015Paroxysmal nocturnal haemoglobinuria (PNH) is a rare, acquired clonal haematological disease characterized by complement-mediated haemolysis, bone marrow failure and venous thrombosis. Anticomplement therapy eculizumab improves survival and reduces complications. Severe acute respiratory distress syndrome corona virus 2 (SARS-CoV-2) disease 2019 (COVID-19) is associated with high incidence of both venous and arterial thrombosis in hospitalized patients with pneumonia. Deep venous thrombosis (DVT) as the presenting symptom of COVID-19 is a rare event. We describe a well-controlled PNH patient on eculizumab for more than 5 years who presented with DVT, while on warfarin, as the first sign of COVID-19. To our knowledge, this is the first described case of DVT in a PNH patient with COVID-19. © 2021 Georg Thieme Verlag. All rights reserved.anticoagulationCOVID-19eculizumabPNHthrombosis